PharmaEngine-B (02617): Sun Delong Appointed as Chief Operating Officer

PharmaXY Health-B (02617) announced that Mr. Sun Delong has been appointed by the company's board of directors as Chief Operating Officer of the company, effective June 12, 2026. In this role, Mr. Sun will be responsible for all aspects of the company's commercial operations. Mr. Sun brings over twenty years of extensive experience in the biopharmaceutical industry, with comprehensive management capabilities spanning the entire value chain—from frontline pharmaceutical marketing and medical affairs promotion to full-scale corporate operations.

Zhitong FinanceJun 12 09:22 ET

PharmaEngine-B shares rose after announcing that pivotal Phase II clinical data for tienogotinib monotherapy in advanced biliary tract cancer will be presented at the 2026 ASCO Annual Meeting.

PharmaEngine-B (02617.HK) rose more than 4%. As of the time of writing, it was up 4.05% at HK$32.74, with a trading volume of HK$45.2553 million.

Zhitong FinanceJun 7 21:48 ET

PharmaEngine-B (02617): Announced pivotal Phase II clinical data of tienogotinib monotherapy in advanced biliary tract cancer at the 2026 American Society of Clinical Oncology (ASCO) meeting

Pharnext-B (02617) announced that the company presented the latest research findings on its core product, tienogotinib monotherapy in Chinese patients with advanced biliary tract cancer previously treated with FGFR inhibitors, as a poster presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago.

Zhitong FinanceMay 31 06:08 ET

TransThera Sciences Completes HK$157 Million Share Offering

MT NewswiresMay 28 00:56 ET

PharmaEngine-B (02617) has completed the issuance of a total of 3,836,000 placing shares.

PharmaXY Health-B (02617) announced that all conditions stipulated in the placing agreement have been satisfied, and the placing was completed on May 27, 2026. The placing agent has successfully placed a total of 3,836,000 placing shares at a placing price of HK$40.83 per placing share to no fewer than six placees.

Zhitong FinanceMay 27 08:55 ET

Hong Kong Stock Market Update | Yaoke AnKang-B (02617) opens more than 8% higher; Phase II clinical trial of enzalutamide in combination with a novel endocrine therapy for metastatic castration-resistant prostate cancer (mCRPC) progressing after prior tre

Yaojie Ankang-B (02617) opened more than 8% higher; as of press time, it was up 8.12% at HK$43.92, with a turnover of HK$2.1082 million.

Zhitong FinanceMay 26 21:24 ET